Literature DB >> 8797469

Specific tau variants in the brains of patients with myotonic dystrophy.

P Vermersch1, N Sergeant, M M Ruchoux, H Hofmann-Radvanyi, A Wattez, H Petit, P Dwailly, A Delacourte.   

Abstract

The mutation causing myotonic dystrophy (DM) is an unstable CTG trinucleotide repeat in a gene encoding for a protein with putative serine-threonine kinase activity. Several studies have reported the appearance of abnormally frequent neurofibrillary tangles (NFTs) in the cortex of patients with DM. Using immunologic probes against normal and pathologic hyperphosphorylated tau proteins, the basic components of NFTs, we performed a biochemical and immunohistochemical study of the brains of two DM cases. We compared the tau profiles with those found in Alzheimer's disease (AD) using mono- and two-dimensional immunoblotting. Patients were aged 53 and 61 years at death. In both cases, we observed few perikaryal and axonal inclusions in the hippocampus as well as the entorhinal and inferior temporal cortices. As in AD brain homogenates, pathologic tau proteins, named tau 55, 64, and 69, were exclusively immunodetected in the DM cases in the hippocampus, the entorhinal cortex, and in most of the temporal areas. Amounts of pathologic tau proteins were higher in the more severely affected case, but lower than in AD brain homogenates. Pathologic tau proteins were less acidic in DM than in AD. We found a very low amount of the tau 69 isoform in DM extracts, and in most of the cortical areas, tau 55 was overexpressed compared with AD homogenates. A link between the increase of kinase activity and the presence of pathologic tau proteins is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797469     DOI: 10.1212/wnl.47.3.711

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

Review 1.  RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Authors:  Gloria V Echeverria; Thomas A Cooper
Journal:  Brain Res       Date:  2012-02-22       Impact factor: 3.252

2.  Cerebral and muscle MRI abnormalities in myotonic dystrophy.

Authors:  Daniel T Franc; Ryan L Muetzel; Paul R Robinson; Craig P Rodriguez; Joline C Dalton; Cameron E Naughton; Bryon A Mueller; Jeffrey R Wozniak; Kelvin O Lim; John W Day
Journal:  Neuromuscul Disord       Date:  2012-01-30       Impact factor: 4.296

3.  Case 12: my doctor says that I have ALS!

Authors:  Robin K Wilson; Vinay Chaudhry
Journal:  MedGenMed       Date:  2006-03-22

4.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 5.  The role of CELF proteins in neurological disorders.

Authors:  Jean-Marc Gallo; Carl Spickett
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

6.  Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study.

Authors:  Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo
Journal:  Neuroradiol J       Date:  2016-01-11

7.  Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1.

Authors:  Jeffrey R Wozniak; Bryon A Mueller; Kelvin O Lim; Laura S Hemmy; John W Day
Journal:  J Neurol Sci       Date:  2014-04-13       Impact factor: 3.181

Review 8.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

Review 9.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

10.  Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study.

Authors:  A Modoni; G Silvestri; M Gabriella Vita; D Quaranta; P A Tonali; C Marra
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.